Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s share price shot up 4.6% during mid-day trading on Thursday . The stock traded as high as $29.85 and last traded at $29.79. 186,192 shares were traded during trading, a decline of 56% from the average session volume of 421,693 shares. The stock had previously closed at $28.47.
Analyst Ratings Changes
Several equities analysts recently commented on COLL shares. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective on the stock in a research report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $43.60.
Check Out Our Latest Report on Collegium Pharmaceutical
Collegium Pharmaceutical Stock Performance
The company's 50-day simple moving average is $30.78 and its 200-day simple moving average is $33.19. The stock has a market capitalization of $928.05 million, a price-to-earnings ratio of 12.70 and a beta of 0.99. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.
Insider Transactions at Collegium Pharmaceutical
In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 93,567 shares of company stock worth $2,774,710 over the last ninety days. 3.98% of the stock is owned by insiders.
Institutional Trading of Collegium Pharmaceutical
A number of large investors have recently bought and sold shares of the business. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at about $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Collegium Pharmaceutical by 11.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock valued at $1,902,000 after buying an additional 7,063 shares during the period. Velan Capital Investment Management LP bought a new position in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $822,000. Vident Advisory LLC boosted its holdings in shares of Collegium Pharmaceutical by 27.8% during the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company's stock worth $484,000 after buying an additional 3,672 shares in the last quarter. Finally, Virtus Fund Advisers LLC grew its position in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 565 shares during the period.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Read More
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
